Connect with us

Government

How Can We Stop the Next Pandemic? We Asked an Epidemiologist

Scanning sewage for disease threats, vaccine safety, and the true origins of COVID-19. We discuss all these topics and more with Dr. David N. Fisman, an epidemiologist at the University of Toronto.

Published

on

Scanning sewage for disease threats, vaccine safety, and the true origins of COVID-19. We discuss all these topics and more with Dr. David N. Fisman, an epidemiologist at the University of Toronto.

It all started with something unimaginably tiny. In fact, if you could see the spiky coronavirus that causes COVID-19 floating midair, it would appear minuscule, even in comparison to the specks of dust floating alongside it. But that’s all it took, a submicroscopic, non-living pathogen to rock the world into chaos, to crash stock markets, to kill millions and to suffocate the world’s economies.

And, despite the panic and havoc the virus continues to cause worldwide – and its “novel” label – it is really nothing new. It has been, in fact, in nature all along, sitting there like a viral time bomb. And epidemiologists were expecting, even warning, that it – or at least something like it – could ignite the next pandemic.

“Most of our vulnerability comes from RNA viruses,” says Dr. David N. Fisman, an epidemiologist at the University of Toronto.

This includes coronaviruses, influenza viruses and a list of other bugs flagged by the World Health Organization as likely threats to mankind.

Why? RNA viruses, as opposed to DNA ones, says Fisman, “mutate and recombine readily, so they pose the greatest threat for novel diseases.”

Dr. DavidundefinedN. Fisman, a professor of epidemiology at the University of Toronto.

Fisman has watched the global COVID-19 outbreak unfold since the start. And he’s got lots of ideas on how to prevent the next pandemic. Both a medical doctor and a professor, Fisman teaches about the epidemiology of infectious diseases at the Dalla Lana School of Public Health in Canada. His research has focused on pneumonia and other epidemic diseases, such as certain intestinal infections and sexually transmitted disease. The Harvard-trained health expert also studies the mathematical modeling and simulation of viral outbreaks.

TheStreet has tapped Fisman for his views on the COVID crisis since weeks before it was officially declared an actual pandemic by the World Health Organization. But, here, he looks forward. Fisman discusses lessons learned, vaccine safety, the murky story of how SARS-CoV-2 jumped to people, and how to get ready for the next global outbreak that’s likely lurking around the corner.

The following exchange was conducted by email and has been lightly edited. It focuses mainly on viral threats and is planned as part of a series of an occasional series of interviews looking ways to prevent the next pandemic.

TheStreet: In my inbox recently was an email for a forum discussion by Harvard's T.H. Chan School of Public Health that began, "Fourteen months into an unprecedented, worldwide pandemic...."

But I don't think this pandemic was unprecedented, and, in the years prior, there was a lot of talk about the 1918 flu pandemic on its 100-year anniversary. SARS and MERS, two other dangerous coronaviruses, as well as Ebola and Zika, had also been in the news in the years prior. Still, most of the world, aside from Taiwan, Hong Kong and Singapore, really failed to act quickly with this virus, and really didn't seem to take it seriously at first. What do you think went wrong?

Fisman: I agree with you entirely in your rejection of this premise. Pandemics aren't a new thing at all. Epidemics and pandemics have been an important part of human history, and there are a lot of echoes of past responses to pandemics in our current situation. A paper by Dr. Peter Juni of St. Michael’s Hospital and colleagues does a wonderful job of showing that 2020 and 1918 are awfully similar. 

I think this feels like an aberration to us because – particularly in rich countries – we've grown very used to the idea that communicable diseases aren't something that can disrupt societies anymore. So, while this is just a repeat of the kind of event that's happened many times in human history, it's been a bit of a comeuppance, especially for wealthy Western countries. I think we've had a lot of competing interests and, frankly, some really bad governance. 

The countries that have done much better during this pandemic have been quick to identify it as an aerosol transmitted disease, have controlled their borders, have listened to science, and have been able to take collective action.

TheStreet: This pandemic really seemed to highlight was a lack of understanding of viral diseases, and that appeared to make people want to put this novel one in a familiar box: the flu or SARS or even the common cold. People seemed surprised that SARS-CoV-2 could be infectious before symptoms appear, that it could have such a long incubation time, and that it could leave many apparently unharmed, while killing and causing severe and sometimes lasting illness in others. But should we have been surprised? Shouldn't all of these been considered as possibilities from the start, instead of relying on airport temperature taking and assuming the virus wouldn't spread beyond Hubei?

Fisman: Again, I concur entirely. Most diseases have a wide spectrum in terms of virulence; pre-symptomatic transmission was something the Chinese were talking about early on. Pre-symptomatic transmission is a factor that really helps determine whether a disease can be controlled, and also, again, implies aerosol transmission of a respiratory disease. We are still struggling with these concepts institutionally in North America. If you can't accept science on how a disease spreads, you're not going to be able to control it.

TheStreet: Looking ahead to preventing or containing the next pandemic, it seems both ideas should be considered, right? So, let's start with surveillance. Talk about some ways world health authorities can boost surveillance to spot the next pandemic?

Fisman: I think we already have some interesting surveillance systems in place that work quite well. ProMED, which is a global email list server on infectious diseases, flagged COVID back around December 2019 or January 2020; they have a history of being out early on other diseases like SARS-1 and MERS. 

Something that's been interesting here in Canada is that web-crawler-based surveillance systems, that were leaned on by WHO and developed in Canada, were actually defunded prior to the pandemic. That's a bit of a scandal here right now, and it's not really clear who gave the order to pull the plug on that alert system, called GPHIN. It makes sense to me that we'd scale stuff like that back up.

An interesting surveillance tool that's really coming into its own during this pandemic is wastewater and sewage surveillance. It is proving to be sensitive and specific for epidemic activity, and one could imagine that being scaled up into a global network for surveillance of priority pathogens. There are already global research networks that look at pathogens in sewage.

One kind of surveillance activity whose role is a bit more questionable after this pandemic is construction of repositories of virulent pathogens gathered from the wild. I think we'll see where we land on the natural emergence vs. lab accident question in Wuhan, but if this pandemic does turn out to be the result of an accidental release from a lab that was engaged in collecting and possibly modifying coronaviruses, that kind of work is really going to have to be looked at carefully after the pandemic. In my opinion, it should be looked at regardless, because even if this was a pandemic that resulted from emergence of the virus in nature, exactly the same thing can happen with accidental lab release.

TheStreet: So, we know these novel diseases ... usually come from wild animals or insects that carry disease, right? We also know that some places, such as China, the world's second largest economy, has been a source of several recent outbreaks: SARS, COVID-19 and bird influenzas H5N1 and H7N9. What are some ways to prevent these types of viral outbreaks from occurring at the source? How much pressure should the world be putting on places like China -- whether this was from a lab or natural spillover -- and how much should it be helping places like Guinea and Sierra Leone or even Mexico and poorer places that are also sources of outbreaks?

Fisman: Yes, around 75% of "novel" emerging infectious diseases happen at the human-animal interface. The drivers of that phenomenon are complex and include how we produce food, including both industrial food production and consumption of bushmeat, increasing sprawl of cities into wilderness areas, and climate and environmental change. This is a paper from 15 years ago from EcoHealth Alliance, a group that's now somewhat in the headlines because of the possibility of lab origins of the current pandemic. 

In China, whatever the origin of SARS-2, it's clear that live animal markets and the trade in wild animals for food create potential vulnerability. Cross species transmission and viral recombination in stressed animals in crowded conditions. But industrial food production and sprawl also create vulnerability. And while economic development for poorer countries is a real positive, transportation infrastructure means that new diseases can move much more quickly from formerly isolated rural areas to global hubs. This happened with Ebola in 2015. So, it's almost the definition of a wicked problem, where you need people who understand economic development, ecology, climate change, food production, and infectious diseases putting their heads together on how to mitigate risk.

An important additional step forward would involve phase I and II trials for vaccines against animal diseases that we know have the potential to jump the species barrier and create a future pandemic: Nipah, Crimean-Congo, Rift Valley Fever, MERS, avian influenza viruses. Having vaccines at least partially developed when a future pandemic unfolds would avoid our current predicament of making vaccines from zero, while fighting a pandemic.

TheStreet: And then, climate change. In the U.S., at least, that's been a huge source of controversy. But aside from its other problems, it can actually contribute to the risk of pandemics, right? Explain.

Fisman: Climate change impacts communicable diseases in a few different ways. In terms of pandemics, I think it's more likely that both climate change and pandemics share upstream drivers in human economic activity and environmental degradation. There's some science-fiction-sounding stuff around defrosting permafrost and viral release, but that's really beyond my pay grade in terms of whether or not that's a threat. The big issues with climate change are: Warmer surface waters are clearly increasing risk of some waterborne diseases – cholera, non-cholera vibrios; increase in fly density has the potential to increase food-borne disease broadly; increased mosquito biting rates at warmer temperatures increases transmission risk for malaria and arboviral diseases like yellow fever and dengue; and diseases like Lyme disease have greater range. Also, disrupted ecology has the potential to increase the risk of zoonotic disease and we are probably seeing this with tularemia in Europe already. And, of course, human migration via desertification, increased sea levels, and war, will predictably have knock-on effects on communicable disease, for example, by increasing refugee and migrant populations.

TheStreet: We also the importance of public health messaging. We really seemed to witness a failure of public health messaging during this pandemic, not just in the U.S. but elsewhere, too. We still have people who don't even believe COVID is real. What are some ways to deal with this? 

Fisman: This is tough stuff. I think clear risk communication, as well as transparency and telling people what they can do to protect themselves, are core public health competencies, but not everyone is great at this part of the job. I remember Dr. Julie Gerberding, who was the Centers for Disease Control and Prevention's director under President George W. Bush, as being a particularly excellent risk communicator, but I'm a big fan of the current director, Dr. Rochelle Walensky, too.

Some of the muddle comes from emerging information being at odds with existing medical dogma. Zeynep Tufekci, an associate professor at the University of North Carolina's School of Information and Library Science, has written about how that's really disrupted messaging on aerosol transmission of COVID-19, where physicians and public health continue to insist that this is a disease that only transmits at short range, which is untrue.

Lastly, we have to deal with a real torrent of misinformation and disinformation, much of it pushed by hostile actors, likely including foreign intelligence services. We have open societies and social media provides tremendous ability to reach and target people. This is article is pretty interesting on some of the weirdness with Great Barrington.

TheStreet: Finally, we seem to have been both lucky and well positioned to have come up with what appear to be really good vaccines for COVID-19 so quickly. But I'm wondering about the PR campaign around them that seems to dismiss any problems associated with them. ... Should governments be more upfront about potential risks, but focus instead on much greater benefits of the vaccines' use during a pandemic? I mean, there's a reason people don't get smallpox vaccines, for example, when there is no risk of infection anymore, and that's partly because the risk of that vaccine outweighs the zero risk of the disease right now. But if that were to reemerge, certainly the vaccine would be far more preferable.

Fisman: We don't use smallpox vaccine anymore because that disease is eradicated, but your larger point about risk-benefit is important and we're seeing that play out right now with the AstraZeneca  (AZN) - Get Report vaccine and vaccine-induced thrombotic thrombocytopenia risk (which is a type of blood clotting along with a simultaneous low blood platelet count). As you say, it's tough to do "phase 4" safety surveillance, because it's hard to assign causality to bad things that happen after vaccines. But the VITT signal was picked up quickly for AZN and the quantitative risk analysis says that in a country like Canada, where we have lots of mRNA vaccine, it doesn't make sense to use AZN. But this is really tricky messaging: Vaccines are very safe, but we hold them to a higher standard than most health interventions, and we're discontinuing use because of safety. I agree: That's tricky. So far, the mRNA vaccines do seem to be remarkably safe and effective, but they're new, so we have to carry on with surveillance

Read More

Continue Reading

International

EUR/AUD bearish breakdown supported by additional China fiscal stimulus and AU inflation

Weak PMI readings from the Eurozone, an increase in China’s budget deficit ratio, and renewed inflationary pressures in Australia may trigger a persistent…

Published

on

  • Weak PMI readings from the Eurozone, an increase in China’s budget deficit ratio, and renewed inflationary pressures in Australia may trigger a persistent bearish sentiment loop in EUR/AUD.
  • Watch the key short-term resistance at 1.6700 for EUR/AUD.
  • A break below 1.6250 key medium-term support on the EUR/AUD may trigger a multi-week bearish impulsive down move.

The Euro (EUR) tumbled overnight throughout the US session as it erased its prior gains against the US dollar recorded on Monday, 23 October; the EUR/USD shed -104 pips from yesterday’s intraday high of 1.0695 to close the US session at 1.0591, its weakest performance in the past seven sessions.

Yesterday’s resurgence of the USD dollar strength has been attributed to a robust set of October flash manufacturing and services PMI data from the US in contrast with weak readings seen in the UK and Eurozone that represented stagflation risks.

Interestingly, the Aussie dollar (AUD) has outperformed the US dollar where the AUD/USD managed to squeeze out a minor daily gain of 21 pips by the close of yesterday’s US session. The resilient movement of the AUD/USD has been impacted by positive news flow out from China, Australia’s key trading partner.

China’s national legislature has just approved a budgetary plan to raise the fiscal deficit ratio for 2023 to around 3.8% of its GDP which was above the initial 3% set in March and set to issue additional sovereign debt worth 1 trillion yuan in Q4. This latest round of additional fiscal stimulus suggests that China’s top policymakers are expanding their initial targeted measures to address the ongoing severe liquidity crunch in the domestic property market as well as to reverse the persistent weak sentiment inherent in the stock market.

In addition, the latest set of Australia’s inflation data surpassed expectations has also reinforced another layer of positive feedback loop in the Aussie dollar which in turn may put Australia’s central bank, RBA on a “hawkish guard” against cutting its policy cash rate too soon.

The less lagging monthly CPI Indicator has risen to an annualized rate of 5.6% in September, above consensus estimates of 5.4%, and surpassed August’s reading of 5.2% which has translated into a second consecutive month of uptick in inflationary growth.

In the lens of technical analysis, a potential bearish configuration setup has emerged in the EUR/AUD cross pair from a short to medium-term perspective.

Major uptrend phase of EUR/AUD is weakening

.

Fig 1: EUR/AUD medium-term trend as of 25 Oct 2023 (Source: TradingView, click to enlarge chart)

Even though the price actions of the EUR/AUD have been oscillating within a major ascending channel since its 25 August 2023 low of 1.4285 and traded above the key 200-day moving average so far, the momentum of this up movement is showing signs of bullish exhaustion.

Yesterday (24 October) price action ended with a daily bearish reversal “Marubozu” candlestick coupled with the daily RSI momentum indicator that retreated right at a significant parallel resistance in place since March 2023 at the 65 level which suggests a revival of medium-term bearish momentum.

EUR/AUD bears are now attacking the minor ascending support

Fig 2: EUR/AUD minor short-term trend as of 25 Oct 2023 (Source: TradingView, click to enlarge chart)

The EUR/AUD has now staged a bearish price action follow-through via the breakdown of its minor ascending support from its 29 September 2023 low after a momentum bearish breakdown that was flashed earlier yesterday (24 October) during the European session as seen from the 4-hour RSI momentum indicator.

Watch the 1.6700 key short-term pivotal resistance (also the 50-day moving average) for a further potential slide toward the intermediate supports of 1.6460 and 1.6320 in the first step.

On the other hand, a clearance above 1.6700 invalidates the bearish tone to see the next intermediate resistance coming in at 1.6890.

Read More

Continue Reading

International

GigXR partners with NUS Medicine to deliver holographic clinical scenarios for gastroenterology training

GigXR, Inc., a global provider of holographic healthcare training, announced today its partnership with the Yong Loo Lin School of Medicine, National University…

Published

on

GigXR, Inc., a global provider of holographic healthcare training, announced today its partnership with the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), one of the world’s leading medical schools, to introduce a new gastrointestinal module for the award-winning HoloScenarios application. Created to better prepare medical and nursing students in diagnosing and treating acute gastrointestinal diseases, HoloScenarios: Gastrointestinal delivers evidence-based, robust clinical simulations that present hyperrealistic holographic simulated patients and medical equipment to be used in any physical learning environment, accessed anywhere in the world.

Credit: Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), and GigXR

GigXR, Inc., a global provider of holographic healthcare training, announced today its partnership with the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), one of the world’s leading medical schools, to introduce a new gastrointestinal module for the award-winning HoloScenarios application. Created to better prepare medical and nursing students in diagnosing and treating acute gastrointestinal diseases, HoloScenarios: Gastrointestinal delivers evidence-based, robust clinical simulations that present hyperrealistic holographic simulated patients and medical equipment to be used in any physical learning environment, accessed anywhere in the world.

Going beyond linear step-based training traditionally seen with virtual reality (VR), HoloScenarios: Gastrointestinal uses mixed reality (MR) to simulate the entire patient journey, while including branching logic to catalyze variance in learning experiences. From taking basic medical history to performing invasive testing and emergency procedures, the new module empowers learners to master vital medical decision-making and manual skills as they would see them in real-life clinical scenarios and patient care.

HoloScenarios: Gastrointestinal is created in collaboration with renowned medical professionals and educators from NUS Medicine who specialize in the fields of Gastrointestinal (GI) Surgery and holographic medical training. The module is delivered by the Gig Immersive Learning Platform, the enterprise-scale platform enabling the creation, curation, and sharing of immersive training applications and modules made by the world’s preeminent healthcare institutions and MR developers.

“Gastrointestinal pathologies can be complex and challenging to diagnose. This module will allow learners to form a deeper understanding and appreciation of the gastrointestinal tract, especially the three-dimensional understanding of anatomy and body functions,” said Associate Professor Alfred Kow Wei Chieh from the school’s Department of Surgery and Assistant Dean (Education) at NUS Medicine. “We believe mixed reality is the next evolution in healthcare training, and collaborating with immersive platform innovators like GigXR helps us to bring this vital content to more learners globally and, ultimately, improve patient care.”

With international medical and surgical credentials that include MBBS (S’pore), M Med (Surg), FRCSEd (Gen Surg), FAMS, and FACS, Associate Professor Kow has trained thousands of healthcare professionals and advanced surgical fellows. He received the 2023 REAL Advancing in Liver Transplantation Award for his contributions to global liver transplantation education and is a founding member of The Holomedicine® Association.

“GigXR has one of the most advanced and comprehensive platforms in mixed reality, especially in medical training, and enables the exchange of developments, innovation, and expertise with a wider community across Asia and beyond,” added Associate Professor Kow. He is also the Head and Senior Consultant of the Division of Hepatobiliary & Pancreatic Surgery, Department of Surgery, at Singapore’s National University Hospital (NUH), the teaching hospital of NUS Medicine.

The new module also delivers enhanced realism in training learners to more accurately diagnose and treat acute gastrointestinal diseases. Whereas VR has been widely used in gastroenterology training for linear step-based skills, such as in endoscopic procedures, it is limited in its ability to simulate fully realized clinical scenarios. Holographic patient simulation in MR merges hyper-realistic holograms in physical learning spaces that accurately reflect the clinical environment and tools with which learners will care for real patients.

With HoloScenarios: Gastrointestinal, learners can interact with the holographic simulated patients, holographic medical equipment, instructors, and each other. This allows them to master both technical and soft skills, such as patient empathy and team communication, in hyper-realistic, safe-to-fail environments that reduce cognitive load. If the holographic patient displays the need for further care, such as a definitive surgery, learners can discuss a definitive treatment plan.

To gain a deeper evaluation of outward symptoms, co-located learners can safely walk around the patient hologram that is displayed on top of their real-world surroundings. Whereas VR locks learners into a virtual “box,” MR enables clear visibility and awareness of physical surroundings. This allows learners to move freely without fear of physical collisions and safety so they can fully focus on learning key gastrointestinal treatment, diagnostic, and communication skills with peers and instructors.

“In healthcare, educators are not only trying to help learners master and retain vital knowledge, but recall and apply it when a patient’s life may be at risk,” said Dr. Gao Yujia, MBBS (S’Pore), MRCS, FRCSEd, Consultant and Assistant Group Chief Technology Officer at Singapore’s National University Health System, and Vice Chairman of The Holomedicine® Association. “With HoloScenarios: Gastrointestinal, learners will have the ability to not only visualize the presentation of a given disease in 3D but better understand how to apply key learnings in the clinical context and within team environments.” Dr Gao is also the Director of Undergraduate Medical Education for Surgery at NUS Medicine.

With scenarios across gastrointestinal pathologies that include gastrointestinal bleeding, intestinal obstruction, and chronic liver failure, learners can master complex and potentially critical situations. They can learn, for example, how to stabilize patients who are dehydrated, bleeding, or septic, as well as the types of diagnostic procedures that may then be required to get a definitive diagnosis. Using mixed reality headsets or any Android, iOS smartphone or tablet, learners can access HoloScenearios: Gastrointestinal from anywhere for remotely distributed, yet highly immersive simulation.

“Immersive technology has accelerated the sharing of expertise for teaching, training, and simulation. Mixed reality, with its natural propensity to facilitate hyperrealistic, safe, and collaborative learning, continues to accelerate both the quality and scale of training outcomes,” said Jared Mermey, CEO of GigXR. “We are immensely proud to partner with NUS Medicine which has been at the forefront of adopting mixed reality in both clinical and educational use cases. By bringing their esteemed expertise onto our platform with the co-creation of HoloScenarios’ newest module, we believe clinical breakthroughs in diagnosing and treating gastrointestinal diseases will take a giant leap forward.”

Designed specifically for pedagogy, the Gig Immersive Learning Platform is trusted by over 70 enterprise-scale healthcare institutions across four continents to build full immersive curricula utilizing a robust content catalog – all of which is managed from a single dashboard. Third-party content developed by leading 3D medical partners, including DICOM Director, 3D4Medical by Elsevier, and ANIMA RES, seamlessly integrates with the platform to provide complementary, in-depth anatomy applications that empower learners with a broader physical context for the pathologies that they study.

“The Gig Immersive Learning Platform has quickly become the premier educational, social network for sharing healthcare training expertise in the immersive format, spanning global healthcare institutions and the Department of Defense to content developers and enterprises large and small,” said David King Lassman, Founder of GigXR. “HoloScenarios: Gastrointestinal marks the latest milestone in our rapidly expanding catalog, which now boasts a dozen different licensable training modules that span holographic simulated patients, clinical scenarios, anatomy, pathophysiology, and 3D medical imaging.”

NUS joins the University of Cambridge and Cambridge University Hospitals (CUH) NHS Foundation Trust, University of Michigan, and Morlen Health, a subsidiary of Northwest Permanente, P.C., as the world-class institutions partnering with GigXR to co-create holographic healthcare training. These simulations include modules centered around Respiratory diseases, Basic Life Support, Advanced Cardiac Life Support, Neurology scenarios, and now, with NUS, Gastrointestinal diseases.

GigXR and NUS Medicine plan to launch HoloScenarios: Gastro in Spring 2024. For more information on GigXR, visit GigXR.com or email sales@gigxr.com. For more information on NUS, visit nus.edu.sg.


Read More

Continue Reading

International

UC Riverside physicist awarded National Medal of Science

RIVERSIDE, Calif. — Physicist Barry C. Barish, a distinguished professor of physics and astronomy at UC Riverside, was awarded the National Medal…

Published

on

RIVERSIDE, Calif. — Physicist Barry C. Barish, a distinguished professor of physics and astronomy at UC Riverside, was awarded the National Medal of Science by President Joe Biden at a ceremony held at the White House today. Established in 1959 by the U.S. Congress, the National Medal of Science is the highest recognition the nation can bestow on scientists and engineers.

Credit: Stan Lim, UC Riverside.

RIVERSIDE, Calif. — Physicist Barry C. Barish, a distinguished professor of physics and astronomy at UC Riverside, was awarded the National Medal of Science by President Joe Biden at a ceremony held at the White House today. Established in 1959 by the U.S. Congress, the National Medal of Science is the highest recognition the nation can bestow on scientists and engineers.

The President’s National Medal of Science is given to individuals “deserving of special recognition by reason of their outstanding contributions in biology, computer sciences, education sciences, engineering, geosciences, mathematical and physical sciences, and social, behavioral, and economic sciences, in service to the Nation.” It is administered by National Science Foundation.

Barish was recognized for “exemplary service to science, including groundbreaking research on sub-atomic particles. His leadership of the Laser Interferometer Gravitational-Wave Observatory led to the first detection of gravitational waves from merging black holes, confirming a key part of Einstein’s Theory of Relativity. He has broadened our understanding of the universe and our Nation’s sense of wonder and discovery.”

“UCR congratulates Prof. Barish on receiving the National Medal of Science,” said UCR Chancellor Kim A. Wilcox. “The distinguished names of previous winners make this recognition very exceptional. Prof. Barish is a strong inspiration for our students, researchers, and faculty. UCR continues to benefit from his extraordinary achievements.”

Barish won the 2017 Nobel Prize in physics for the discovery of gravitational waves. He joined the UCR faculty in 2018. He earned his bachelor’s degree in physics in 1957 and his doctorate in experimental particle physics in 1962, both from from UC Berkeley. He joined Caltech as a postdoc in 1963, became a professor in 1966, and was appointed Linde Professor of Physics in 1991. He led the Laser Interferometer Gravitational-wave Observatory, or LIGO, effort from its inception through the final design stages, and in subsequent discoveries. In 1997, he created the LIGO Scientific Collaboration, which enables more than 1,000 collaborators worldwide to participate in LIGO.

Barish has served on many committees, including co-chairing the subpanel of the High Energy Physics Advisory Panel that developed a long-range plan for U.S. high-energy physics in 2001. He chaired the Commission of Particles and Fields and the U.S. Liaison Committee to the International Union of Pure and Applied Physics.

He is the recipient of the Fudan-Zhongzhi Science Award (China), Princess of Asturias Prize for Science and Technology (Spain), Giuseppe and Vanna Cocconi Prize from the European Physical Society, the Enrico Fermi Prize from the Italian Physical Society, and the Klopsteg Award from the American Association of Physics Teachers. He is a member of the National Academy of Sciences, which awarded him the Henry Draper Medal. From 2003 to 2010, he served as a presidential appointee to the National Science Board.

He is an elected member of the American Academy of Arts and Sciences and a fellow of both the American Association for the Advancement of Science and of the American Physical Society, where he also served as president. He has received honorary doctorates from the University of Bologna, University of Florida, University of Glasgow, and Universitat de València in Spain. He has been inducted as honorary academician into the Royal Academy of European Doctors, based in Spain. He was elected a foreign member of the Royal Society in 2019. Last year, he won the Copernicus Prize, bestowed by the government of Poland. Earlier this year, he was elected a corresponding member of the Royal Academy of Sciences and Arts of Barcelona. 

The University of California, Riverside is a doctoral research university, a living laboratory for groundbreaking exploration of issues critical to Inland Southern California, the state and communities around the world. Reflecting California’s diverse culture, UCR’s enrollment is more than 26,000 students. The campus opened a medical school in 2013 and has reached the heart of the Coachella Valley by way of the UCR Palm Desert Center. The campus has an annual impact of more than $2.7 billion on the U.S. economy. To learn more, visit www.ucr.edu.


Read More

Continue Reading

Trending